BMJ  2007;334:55-56 (13 January), doi:10.1136/bmj.39049.545880.BE

Editorials

Food and Drug Administration

More independent resources and alternative ways to identify adverse events are key

The first 150 words of the full text of this article appear below.

The Food and Drug Administration of the United States is now the patient on the examining table, with no shortage of attending doctors or nostrums. Months ago, the agency sought the advice of the National Academy of Sciences' Institute of Medicine on its drug safety system. The resulting report echoed previous suggestions that the agency should be given more money and power and proposed altering current industry approaches to drug development.1 2 3 4 The drug industry, already smarting from tightened FDA drug safety standards, went into defensive mode.

The Institute of Medicine report will certainly play a key part in an upcoming debate in Congress over renewal of legislation that empowers the FDA to collect fees for a portion of the cost of reviewing applications for drug approval. The current user fee legislation expires 30 September 2007 and must be reauthorised by then; this will provide a vehicle for new drug safety . . . [Full text of this article]

Linda R Horton, partner

1 Hogan and Hartson, B-1040 Brussels, Belgium

lrhorton@hhlaw.com


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to StumbleUpon StumbleUpon   Add to Technorati Technorati    What's this?
Access jobs at BMJ Careers
Whats new online at Student BMJ